Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors | Breast Cancer Research | Full Text

Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors | Breast Cancer Research | Full Text

Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors

Addition of CDK4/6 inhibitors (CDK4/6i) to endocrine therapy significantly increased progression-free survival, leading to their approval and incorporation into the metastatic breast cancer treatment paradigm....

Authors:Hitisha K. Patel, Nianjun Tao, Kyung-Min Lee, Mariela Huerta, Heike Arlt, Tara Mullarkey, Steven Troy, Carlos L. Arteaga and Teeru Bihani

Citation:Breast Cancer Research 2019 21:146

Content type:Research article

Published on: 18 December 2019

• ViewFull Text
 
• ViewPDF